Delivery Order GS10F0105J-EP1106

The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $60,000 firm fixed price delivery order to Central Admixture Pharmacy Services, Inc. for 503A compounded products for patient care. As the prime contractor, Central Admixture Pharmacy Services, Inc. will provide compounded medications from its central admixture pharmacy in Irvine, California in support of clinical care at the NIH Clinical Center. No set-aside designation was used for this contract...

The National Institutes of Health Clinical Center awarded a purchase order to Central Admixture Pharmacy Services, Inc. (Caps) on July 11, 2019, for compounded sterile products, with a ceiling value of $21,599.64 and a firm fixed-price arrangement. Performance is based in Irvine, California. The order calls for compounded sterile pharmaceutical preparations, including total parenteral nutrition solutions, sterile admixtures, intravenous mixtures, and related customized pharmaceutical products to...

<p>The NIH Clinical Center issued a $50,000 delivery order to Central Admixture Pharmacy Services, Inc. on January 1, 2020, for 503B compounded pharmaceutical products as needed from its central admixture pharmacy services.</p> <p>Place of performance is Irvine, CA. The order carries a firm fixed price and ultimate completion date of September 30, 2020. No set-aside was used.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to On Demand Pharmaceuticals Inc. The contract is for the development of small manufacturing systems to produce research-grade pharmaceutical intermediates, under SBIR Topic 024. The contract is a firm-fixed-price definitive contract with a ceiling value of $325,000.00 and an ultimate completion date...

<p>The NIH Clinical Center issued a delivery order to Amerisourcebergen Drug Corp on January 30, 2013, with a ceiling value of $55,928.82 for pharmaceutical supply.</p> <p>Place of performance is Glen Allen, VA. The order was priced on a firm fixed-price basis and reached final close on February 28, 2013.</p>

The National Institute on Drug Abuse issued a purchase order to Avista Pharma Solutions, Inc. (doing business as Cambrex) on December 31, 2020, valued at $2,086,294.30 for the acquisition of cGMP-grade GS-441524 drug substance to support COVID-19 treatment research. Place of performance is Durham, North Carolina. The order calls for manufacturing of cGMP-grade GS-441524 to support preclinical and Phase I clinical studies evaluating the drug's safety, tolerability, efficacy, pharmacokinetics, and...

<p>NIH Clinical Center awarded a purchase order to Central Admixture Pharmacy Services, Inc. for $23,197.50 on May 31, 2019, with completion by October 31, 2019. No set-aside was used. Performance occurs in Irvine, California. The order is firm fixed price for compounded sterile pharmaceutical preparations, including total parenteral nutrition solutions and sterile admixtures, supporting federal healthcare operations.</p>

This is a task order award to Bachem Americas Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for a 3-year stability study extension on a cGMP batch of the drug substance leucine enkephalin (L-ENK). The $56,100.00 firm fixed-price award was made by the National Institute on Drug Abuse, a civilian agency within the Department of Health and Human Services. The task order is part of a larger $49,713,679.00 Indefinite Delivery/Indefinite Quantity (IDIQ) contract held by Bachem...

<p>The National Institutes of Health Clinical Center issued a delivery order to AmerisourceBergen Drug Corp on February 20, 2013, with a ceiling value of $56,084.06 for pharmaceutical supply.</p> <p>Place of performance is Glen Allen, VA. The order was firm fixed price with an ultimate completion date of March 21, 2013.</p>

The National Institutes of Health Clinical Center issued a $34,558.74 delivery order to Amerisourcebergen Drug Corp on June 5, 2013, for pharmaceutical products and medical supplies. Place of performance is Glen Allen, VA. The order has a firm fixed price structure and an ultimate completion date of July 5, 2013. No set-aside was used. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a major pharmaceutical distributor serving federal healthcare systems including the Department of...